KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBIT Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBIT Margin for 11 consecutive years, with 969.84% as the latest value for Q1 2025.

  • Quarterly EBIT Margin changed N/A to 969.84% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 689.79% through Dec 2025, changed N/A year-over-year, with the annual reading at 689.79% for FY2025, N/A changed from the prior year.
  • EBIT Margin for Q1 2025 was 969.84% at Xenon Pharmaceuticals, up from 28884.85% in the prior quarter.
  • The five-year high for EBIT Margin was 198.14% in Q1 2022, with the low at 28884.85% in Q3 2022.
  • Average EBIT Margin over 3 years is 4762.84%, with a median of 817.25% recorded in 2021.
  • Peak annual rise in EBIT Margin hit 17035bps in 2022, while the deepest fall reached -2853823bps in 2022.
  • Over 3 years, EBIT Margin stood at 664.65% in 2021, then crashed by -4246bps to 28884.85% in 2022, then skyrocketed by 97bps to 969.84% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 969.84%, 28884.85%, and 5655.78% for Q1 2025, Q3 2022, and Q2 2022 respectively.